One of MassBioEd’s most popular courses, Biotech 101 for Non-Scientists is being offered THIS WEEK Sept. 18 – 19, and also this winter, December 4 – 5!
To register for FALL, click here.
To register for WINTER, click here.
**MassBio members get a $150 discount on registration**
Are you new to the life sciences industry? Do you need to have a better understanding of the science and technology driving the industry? Biotech 101 is a course designed specifically for the non-scientists. The program covers two full days of biotechnology information for non-science professionals who may be working on looking to work within a science-based industry.
Participants will benefit from several hands on activities using Lego DNA models, Agarose Gels, in addition to a DNA exercise featured here: http://youtu.be/JwRs2agM3Lk
Don’t miss the Fierce 15!
John Carroll, Editor-in-Chief of FierceBiotech, will be giving a live announcement of the Fierce 15 at BioPharm America again this year! The Fierce 15 is a hunt that involves the biggest ideas in biotech, the most daring characters in biopharma, and entrepreneurs doing things that haven’t been done before. The Fierce 15 will include drug developers or platform biotechs with the potential to have a huge impact on the treatment of human diseases. Be there when the news breaks!
Check out the keynote & opening plenary!
The Keynote Address will be given by Gary Nabel, Chief Scientific Officer at Sanofi, and will also join the Opening Plenary.
These are exciting times, because pharma companies are going back to their roots. There’s been a major shift toward external innovation and data-driven science that guides the development of new medicines. For academic research, we see more collaboration at earlier stages. For biotech, we see relationships built at different points in the evolution of new medicines, and we are using structures and support that incentivize both partners to achieve success,” said Nabel.
The Opening Plenary will address “Getting real: Biopharma innovation and its impact on patients” with:
- Barry Greene, President and COO at Alnylam Pharmaceuticals
- Adam M. Koppel, Senior VP and Chief Strategy Officer at Biogen Idec
- Richard Pops, Chairman and CEO at Alkermes plc.
- Karen Bernstein, Co-Founder, Chairman, and Editor-in-Chief at BioCentury (Moderator)
Global pharmaceutical companies already confirmed to send business development teams to BioPharm America include AstraZeneca; Bayer HealthCare; Bristol-Myers Squibb; EMD Serono; Merck; Novo Nordisk; Sanofi; and Shire.
BioPharm America, being held September 22-24 in Boston, is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, the world’s leading web-based partnering system for the life science industry, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Partnering, facilitated by EBD Group’s online partnering system partneringONE®, is the most efficient way to find and meet the right people for your company’s collaborative aims.
11 meetings in 2½ days
The average company has 11 meetings with existing and potential partners, customers and clients in 2½ days.
Benefits of partneringONE®:
- Conduct more meetings at one conference than in the rest of the year
- Contact existing and potential partners prior to the conference
- Manage all your conference activities in one place
- Your meetings will be prescheduled to maximize your time on site.
***MassBio members get $200 off – mention Massbio in the registration comments field!***
“We had a first partnering meeting with Teva at this conference a year ago. At this year’s event we are announcing the closing of a deal with Teva worth a potential $165M. That is what I call a return on investment in a conference!”
– CEO, Rexahn Pharmaceutical
“Partnering starts with science scouts who are trolling their territories to find gems for us. These kinds of candidates are here, giving us the opportunity to screen 20 potential investment opportunities in a very short period of time. Doing this otherwise would require significant travel and time.”
– Executive Director, Corporate Licensing, Merck & Co.
“Four people from my company were attending one-to-one meetings at the event seeking out opportunities to build up companies and novel programs from scratch. “
– Life Sciences Partner, Atlas Venture
The BioPharm America 2014 Program Overview is now available online!
MassBio members save $200 on registration! Be sure to mention MassBio in the registration comments field!
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, the world’s leading web-based partnering system for the life science industry, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Keynote speakers include:
Flemming Ornskov, CEO of Shire
Gary Nabel, CSO of Sanofi
Sessions will cover:
- The Perfect Pitch: Do you Have What it Takes to Win Over Investors?
- How Unconventional Pharma & VC Collaborations are Expanding R&D Budgets
- The Pressures of Being an Early Stage Public Company
- Clinical Outlook for New Immuno-Oncology Treatments
- Key Partnerships in Advanced Therapies: Pharma May Have Company
- The Power of the Patients: How Patients are Getting Things Done in the Drug Development Process
- And more!
BioPharm America™ 2013 Highlights
- 900+ attendees
- 2,950 one-to-one meetings
- 757 licensing opportunities posted
- 550 companies
- 75 company presentations
- 15 exhibitors
- 35 countries represented
- 20 workshops and panels
North Carolina’s Argos Therapeutics raked in $45 million in a below-its-range Wall Street debut, sticking a so-so endcap on an otherwise colossal week for biotech IPOs in which drug developers banked more than $500 million. Link
2) Big Pharma superteam joins NIH to share data, discover new drugs - Fierce Biotech, February 4, 2014
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts. Link
3) X-Chem aims at more partnerships with fast screening method – Boston Business Journal, February 5, 2014
Wagner gave details for the first time today about why he thinks his Waltham biotech can help pharmaceutical companies dramatically increase their odds of discovering a drug for any given disease. Link
4) Hopes of family, firm collide on unproven drug - The Boston Globe, January 31, 2014
Jamie and Jason Fowler arrived early at a Chicago airport hotel on a recent Saturday morning, eager to meet the pharmaceutical executive from Massachusetts they hoped would help save the life of their 6-year-old son, Jack. Link
5) Governor Patrick and the Massachusetts Life Sciences Center Celebrate the Opening of the New Vertex Facility in Boston - MassBio.org/news, February 4, 2014
Governor Deval Patrick today joined Vertex Pharmaceutical’s leadership, industry stakeholders and state and local officials to celebrate the grand opening of the company’s new 1.1 million-square-foot global headquarters at 11 Fan Pier Boulevard in Boston. Link